In 2014, Japanese Ministry of Health, Labour and Welfare published the guideline on the policy of the psychiatric hospitals. We executed a survey to the members of "The Japanese Society of Psychiatry and Neurology" about the impression of this guideline, especially about "The functional differentiation of psychiatric hospital beds". Nine questions were notified on the home page of the society. 862 answers (5.3% of the members) were corrected by website from 1st to 30th of May in 2015. Attribution of the answers : doctors working at the psychiatric hospitals (70.9%), the psychiatric clinics (20%), the others (9.1%). The questions which more than 80% of the answers agreed were "The reduction of the psychiatric beds should be stepwise under the rule of check & balance in the improvement of the psychiatric community treatment", "Improve the function of the recovery phase treatment" and "The adequate treat- ment for the patients of the severe and chronic phases". The questions more than 55% of the answers agreed were "The reduction of the chronic phase beds for the improvement of the function of the acute phase beds". The questions which opposites exceeded (almost 47%) were "The assessment of the psychiatric symptoms in the patients of the chronic phase should be done by the third party" and "The facility for social skill treatment should be placed in the community". We could know the mind of the members about the revolution of the psychiatric.
To examine antidepressant prescription patterns in Japanese children and adolescents. We conducted a cross-sectional survey during October 2013 on outpatients, aged 19 or less, in 34 private mental clinics. Patients who were prescribed at least one antidepressant were analyzed in this report. Data on gender, age, principal psychiatric diagnosis (based on ICD-10), and types and doses of psychotropic drugs were extracted. The samples consisted of 137 males and 170 females. The average age (standard deviation) was 16.2 years (2.5). The mean length of psychiatric treatment was 23.6 months (23.3). The most frequent diagnostic category was neurotic disorders (F4; n=113), followed by mood disorders (F3; n=73), disorders of psychological development (F8; n=67), behavioral and emotional disorders (F9; n=22), schizophrenic spectrum disorders (F2; n=18), and other diagnoses (n=14). Among the 19 antidepressants available in Japan, the prescription rate of fluvoxamine (42.3%; n=130) was the highest, followed by sertraline (17.6%), duloxetine (10.4%), escitalopram (9.8%), trazodone (6.5%), and paroxetine (5.5%). Tricyclic or tetracyclic antidepressants (TCAs) were prescribed in 35 patients (11.4%). Two or more antidepressants were prescribed concurrently in 27 (8.8%) of the 307 patients. Anxiolytics/hypnotics were concurrently prescribed in 126 (41.0%). Mood stabilizers were co-prescribed in 35 (11.4%). Antipsychotics were concurrently prescribed in 134 (43.6%), with a median dose of 100mg/d chlorpromazine equivalent. In Japan, although augmentation of antidepressant treatment seemed relatively popular with antipsychotics in adolescent patients, antipsychotic doses might be relatively low.